Format

Send to

Choose Destination
Br J Cancer. 2018 Aug;119(3):347-356. doi: 10.1038/s41416-018-0172-0. Epub 2018 Jul 10.

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.

Author information

1
Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere, Tampere, Finland. heini.kallio@uta.fi.
2
Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere, Tampere, Finland.
3
Department of Urology, University of Tampere, Tampere University Hospital, Tampere, Finland.
4
The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
5
Departments of Surgery (Urology), Laboratory Medicine and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
6
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
7
Department of Translational Medicine, Lund University, Malmö, Sweden.
8
Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.

Abstract

BACKGROUND:

A significant subset of prostate cancer (PC) patients with a castration-resistant form of the disease (CRPC) show primary resistance to androgen receptor (AR)-targeting drugs developed against CRPC. As one explanation could be the expression of constitutively active androgen receptor splice variants (AR-Vs), our current objectives were to study AR-Vs and other AR aberrations to better understand the emergence of CRPC.

METHODS:

We analysed specimens from different stages of prostate cancer by next-generation sequencing and immunohistochemistry.

RESULTS:

AR mutations and copy number variations were detected only in CRPC specimens. Genomic structural rearrangements of AR were observed in 5/30 metastatic CRPC patients, but they were not associated with expression of previously known AR-Vs. The predominant AR-Vs detected were AR-V3, AR-V7 and AR-V9, with the expression levels being significantly higher in CRPC cases compared to prostatectomy samples. Out of 25 CRPC metastases that expressed any AR variant, 17 cases harboured expression of all three of these AR-Vs. AR-V7 protein expression was highly heterogeneous and higher in CRPC compared to hormone-naïve tumours.

CONCLUSIONS:

AR-V3, AR-V7 and AR-V9 are co-expressed in CRPC metastases highlighting the fact that inhibiting AR function via regions common to all AR-Vs is likely to provide additional benefit to patients with CRPC.

PMID:
29988112
DOI:
10.1038/s41416-018-0172-0

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center